Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 6/20 | 0.36 |
| ▸ | FAP | Q12884 | 6/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 6/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.36 |
| ▸ | MC4R | P32245 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14147591 | 1.00 | DPP4 (0.36) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL1748909 | 1.00 | DPP4 (0.36) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL2898102 | 0.97 | DPP4 (0.36) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL2898105 | 0.97 | DPP4 (0.36) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL1748929 | 0.90 | MC4R (0.37) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL1748928 | 0.90 | MC4R (0.37) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL14291580 | 0.88 | DPP4 (0.46) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL1748573 | 0.87 | MC4R (0.36) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL1748571 | 0.87 | MC4R (0.36) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL5031635 | 0.87 | MC4R (0.36) | DPP4FAPDPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968548-B2 | Agonist or antgonist and binders and inversion of agonist; use in the treatment of metabolic, immune, infection-related and melanocortin receptor mediated disorders including specifically treatment of obesity and related conditions | PALATIN TECHNOLOGIES, INC. (US) | 2011-06-28 | — | — | US | claimed |
| EP-1922072-A2 | MELANOCORTIN RECEPTOR-SPECIFIC PIPERAZINE COMPOUNDS WITH DIAMINE GROUPS | Palatin Technologies, Inc. (US) | 2008-05-21 | — | — | EP | claimed |
| US-20080070921-A1 | Diamine-Containing, Tetra-Substituted Piperazine Compounds Having Identical 1- and 4-Substituents | PALATIN TECHNOLOGIES, INC. (US) | 2008-03-20 | — | — | US | claimed |
| WO-2007021990-A2 | MELANOCORTIN RECEPTOR-SPECIFIC PIPERAZINE COMPOUNDS WITH DIAMINE GROUPS | PALATIN TECHNOLOGIES, INC. (US) | 2007-02-22 | — | — | WO | claimed |
| US-20060287331-A1 | MELANOCORTIN RECEPTOR-SPECIFIC PIPERAZINE COMPOUNDS WITH DIAMINE GROUPS | PALATIN TECHNOLOGIES, INC. (US) | 2006-12-21 | — | — | US | claimed |
| US-7968548-B2 | Agonist or antgonist and binders and inversion of agonist; use in the treatment of metabolic, immune, infection-related and melanocortin receptor mediated disorders including specifically treatment of obesity and related conditions | PALATIN TECHNOLOGIES, INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968548-B2 | Agonist or antgonist and binders and inversion of agonist; use in the treatment of metabolic, immune, infection-related and melanocortin receptor mediated disorders including specifically treatment of obesity and related conditions | PALATIN TECHNOLOGIES, INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968548-B2 | Agonist or antgonist and binders and inversion of agonist; use in the treatment of metabolic, immune, infection-related and melanocortin receptor mediated disorders including specifically treatment of obesity and related conditions | PALATIN TECHNOLOGIES, INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7834017-B2 | Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents | PALATIN TECHNOLOGIES, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834017-B2 | Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents | PALATIN TECHNOLOGIES, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834017-B2 | Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents | PALATIN TECHNOLOGIES, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| WO-2008090357-A2 | N, N; -SUBSTITUTED PIPERAZINES BINDING TO MELANOCORTIN RECEPTOR | PALATIN TECHNOLOGIES, INC. (US) | 2008-07-31 | — | — | WO | disclosed |
| EP-1922072-A2 | MELANOCORTIN RECEPTOR-SPECIFIC PIPERAZINE COMPOUNDS WITH DIAMINE GROUPS | Palatin Technologies, Inc. (US) | 2008-05-21 | — | — | EP | disclosed |
| US-20080070921-A1 | Diamine-Containing, Tetra-Substituted Piperazine Compounds Having Identical 1- and 4-Substituents | PALATIN TECHNOLOGIES, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| US-20080070921-A1 | Diamine-Containing, Tetra-Substituted Piperazine Compounds Having Identical 1- and 4-Substituents | PALATIN TECHNOLOGIES, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| US-20080070921-A1 | Diamine-Containing, Tetra-Substituted Piperazine Compounds Having Identical 1- and 4-Substituents | PALATIN TECHNOLOGIES, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| WO-2008017852-A1 | DIAMINE-CONTAINING, TETRA- SUBSTITUTED PIPERAZINE COMPOUNDS AS MELANOCORTIN RECEPTOR MODULATORS | PALATIN TECHNOLOGIES, INC. (US) | 2008-02-14 | — | — | WO | disclosed |
| WO-2007021990-A2 | MELANOCORTIN RECEPTOR-SPECIFIC PIPERAZINE COMPOUNDS WITH DIAMINE GROUPS | PALATIN TECHNOLOGIES, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| US-20060287331-A1 | MELANOCORTIN RECEPTOR-SPECIFIC PIPERAZINE COMPOUNDS WITH DIAMINE GROUPS | PALATIN TECHNOLOGIES, INC. (US) | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070921-A1 | Diamine-Containing, Tetra-Substituted Piperazine Compounds Having Identical 1- and 4-Substituents | NPY1R, MC5R, MC4R | DPP4 1448/4885FAP 3309/4885DPP8 2666/4885 |
| US-20060287331-A1 | MELANOCORTIN RECEPTOR-SPECIFIC PIPERAZINE COMPOUNDS WITH DIAMINE GROUPS | MC4R, MC1R, MC5R | DPP4 820/4885FAP 2886/4885DPP8 1158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.